1. Home
  2. MC vs IOVA Comparison

MC vs IOVA Comparison

Compare MC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moelis & Company

MC

Moelis & Company

HOLD

Current Price

$69.20

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.21

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MC
IOVA
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
968.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
MC
IOVA
Price
$69.20
$2.21
Analyst Decision
Buy
Buy
Analyst Count
9
12
Target Price
$73.50
$10.36
AVG Volume (30 Days)
852.7K
9.8M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
3.73%
N/A
EPS Growth
446.16
N/A
EPS
3.17
N/A
Revenue
$1,467,580,000.00
$250,425,000.00
Revenue This Year
$27.25
$60.94
Revenue Next Year
$17.11
$60.85
P/E Ratio
$22.00
N/A
Revenue Growth
51.19
175.62
52 Week Low
$47.00
$1.64
52 Week High
$82.89
$8.56

Technical Indicators

Market Signals
Indicator
MC
IOVA
Relative Strength Index (RSI) 61.66 46.56
Support Level $62.77 $2.18
Resistance Level $72.26 $2.32
Average True Range (ATR) 2.17 0.12
MACD 0.89 -0.01
Stochastic Oscillator 74.16 18.11

Price Performance

Historical Comparison
MC
IOVA

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: